To cure AIDS as the goal! FDA approves Phase I clinical treatment of GENE Technology Corporation (AGT) to advance HIV treatment program.

AIDS has affected society for more than forty years.
worldwide, nearly 38 million people are infected with HIV, and in the United States, more than 1 million people are infected with HIV.
so far, efforts to cure the disease have been unsuccessful.
American Genenure Technology Corporation (AGT) announced today that it has received FDA approval to begin Phase I clinical trials to test the effectiveness and safety of gene therapy AGT103-T for AIDS treatment, the first human trial of AGT103-T.
AGT will conduct its Phase I study at the Washington Institutes of Health, the University of Maryland, the Human Virus Institute and the Georgetown University Clinical Center.
are expected to begin registration in September 2020, and AGT hopes to report initial data by the end of the year.
Phase I clinical trial of AGT will study the safety of AGT103-T, measure key biomarkers, and explore alternative markers of efficacy.
AGT103-T is a slow virus vector-based gene therapy designed to completely eliminate HIV, which repairs damage to the immune system caused by HIV and allows a natural immune response to control the virus.
according to its research, AGT believes that AGT103-T can cure AIDS.
AGT103-T cell product is made by blood cells after an 11-day process that increases the number of T-cells fighting HIV and uses gene therapy to help them survive in the body.
preclinical studies have shown that AGT103-T can remove HIV.
AGT's characterism for AGT103-T was developed in collaboration with the National Institutes of Health's National Institutes of Allergy and Infectious Diseases (NIAID).
peer-reviewed paper, co-authored by AGT and NIAID scientists, was published in Molecular Therapy in June 2020, describing the evolution of the AGT103-T manufacturing process.
.